Ixabepilone and other epothilones: Microtubule-targeting agents for metastatic breast cancer

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 2, 2009, Pages 115-122

  Morris, Patrick G ^a   Fornier, Monica N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epothilones; Ixabepilone; Metastatic breast cancer; Neurotoxicity; Taxanes

Indexed keywords

21 AMINOEPOTHILONE B; 9,10 DIDEHYDROEPOTHILONE D; ABJ 879; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYTOTOXIC AGENT; DOXORUBICIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; KOS 682; LAPATINIB; MACROLIDE; PACLITAXEL; SAGOPILONE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; N(DELTA) (5 METHYL 4 OXO 2 IMIDAZOLIN 2 YL)ORNITHINE; N(DELTA)-(5-METHYL-4-OXO-2-IMIDAZOLIN-2-YL)ORNITHINE; ORNITHINE; TUBULIN MODULATOR;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; DRUG USE; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY REACTION; LUNG NON SMALL CELL CANCER; METASTASIS; MICROTUBULE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERIPHERAL NEUROPATHY; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; TUMOR RESISTANCE; UNITED STATES; VOMITING; BREAST TUMOR; DRUG DESIGN; FEMALE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; EPOTHILONES; FEMALE; HUMANS; IMIDAZOLES; NEOPLASM METASTASIS; ORNITHINE; TUBULIN MODULATORS;

EID: 65649092139     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
3. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
4. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2neu positive early breast cancer patients. In: Proceedings of the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006. abstract.
5. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
6. Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo). 1996;49:560-563.
7. Bode CJ, Gupta ML Jr, Reiff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry. 2002;41:3870-3874.
8. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325-2333.
9. Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem. 2004;279:39431-39437.
10. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science. 2004;305:866-869.
11. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429-437.
12. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents. 2002;2:123-148.
13. Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;S5:v9-15.
14. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol. 2003; 21:1866-1873.
15. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res. 2004;10:1289-1298.
16. Shimizu T, Yamamoto N, Yamada Y, et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol. 2008;61:751-758.
17. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23:2726-2734.
18. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25:3415-3420.
19. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007; 25:3421-3427.
20. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-3414.
21. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25:3399-3406.
22. Baselga J, Zambetti M, Llombart-Cussac A. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol. 2008; Dec 15 [Epub ahead of print].
23. Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a phase I/ II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006; 24(18S):10511.
24. Moulder S, Wang M, Gradishar W, et al. A phase II trial of trastuzumab, weekly ixabepilone (BMS-247550) and carboplatin (TIC) in patients with HER2/neu-positive (HER2+) metastatic breast cancer (MBC): a trial coordinated by the Eastern Cooperative Oncology Group (E2103). Breast Cancer Res Treat. 2007;106: S1(Abstr 6070)
25. Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007;25:3448-3455.
26. Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23:8724-8729.
27. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005;23:1439-1446.
28. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556-563.
29. Whitehead RP, McCoy S, Rivkin SE, et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs. 2006;24:515-520.
30. Zhuang SH, Menefee M, Kotz H et al. A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2004;22(14S):4550.
31. Pavlick AC, Millward M, Farrell K, et al. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM). J Clin Oncol (ASCO Annual Meeting Abstracts). 2004;22(14S):7542.
32. Okuno S, Maples WJ, Mahoney MR, et al. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol. 2005;23:3069-3073.
33. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-5217.
34. Lee FY, Camuso A, Castenada C, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24:12017.
35. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3. Available at www.fda.gov/cder/cancer/toxicityframe.htm
36. Traina TA, Theodoulou M, Feigin K, et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol. 2008;26:1797-1802.
37. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799.
38. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
39. Lin B, Catley L, LeBlanc R, et al. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. 2005;105: 350-357.
40. Mok TS, Choi E, Yau D, et al. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology. 2006;71:292-296.
41. O'Reilly T, Wartmann M, Maira SM, et al. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol. 2005;55:307-317.
42. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015-2025.
43. Abrey L, Wen P, Govindan R et al. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II study. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25(18S):18058.
44. Phase II Trial of Patupilone in Patients With Brain Metastases From Breast Cancer NCT00450866. Available at http://clinicaltrials.gov/ct2/ show/NCT00450866
45. Sessa C, Perotti A, Lladò A, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol. 2007;18: 1548-1553.
46. Wartmann M, Loretan J, Reuter R, et al. Preclinical pharmacological profile of ABJ879, a novel epothilone B analog with potent and protracted anti-tumor activity. Proc Amer Assoc Cancer Res. 2004;45:Abstract 5440.
47. Klar U, Buchmann B, Schwede W, et al. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl. 2006;45:7942-7948.
48. Hoffmann J, Vitale I, Buchmann B, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res. 2008;68:5301-5308.
49. Rustin G, Reed N, Jayson G, et al. Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25(18S):5527.
50. Beer TM, Higano CS, Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs. 2007;25:565-570.
51. Marshall J, Ramalingam S, Hwang J, et al. Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts). 2005;23(16S):2041.
52. Overmoyer B, Waintraub S, Kaufman P, et al. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2005;23(16S):778.
53. Stopeck A, Moulder S, Jones S, et al. Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25(18S):2571.